FDA: Alvogen recalls seven lots of clindamycin

Editor's Note

The Food and Drug Administration (FDA) on June 16 announced the recall by Alvogen/Hospira Inc, a Pfizer company, of seven lots of Clindamycin Injection USP ADD-Vantage Vials.

The recall was initiated because microbial growth was detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the product.

To date, the company has not received any reports of adverse events associated with use of the product.

Posted 06/16/2017] AUDIENCE: Pharmacy, Health Professional, Infectious Disease ISSUE: Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the product.